Back to top
more

Zoetis (ZTS)

(Delayed Data from NYSE)

$179.66 USD

179.66
1,309,270

+0.28 (0.16%)

Updated Jul 24, 2024 04:00 PM ET

Pre-Market: $179.66 0.00 (0.00%) 9:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).

Zoetis (ZTS) Up 6.4% Since Earnings Report: Can It Continue?

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet

    Roche Holding AG (RHHBY) announced new retrospective data analyses for idiopathic pulmonary fibrosis (IPF) drug, Esbriet.

      Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data

      Inovio Pharmaceuticals Inc. (INO) shares have rallied 12% since the company announced that its HIV vaccine evoked almost 100% immune response rates in a clinical study

        Horizon (HZNP) Sells European Rights for Procysbi & Quinsair

        Horizon Pharma plc (HZNP) signed an agreement with Chiesi Farmaceutici S.p.A. to sell European rights for Procysbi and Quinsair.

          Roche's Arthritis Drug Gets FDA Nod for Label Expansion

          Roche Holdings AG (RHHBY) announced that the FDA has approved Actemra subcutaneous injection for the treatment of giant cell arteritis (GCA).

            Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint

            Celgene Corporation (CELG) announced positive results from the phase III trial, RADIANCE that evaluated the efficacy and safety of experimental candidate ozanimod.

              Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study

              Adamas Pharmaceuticals, Inc. (ADMS) announced positive data from thephase Ia study evaluating ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy.

                AstraZeneca Sells Marketing Rights to Seloken in Europe

                AstraZeneca plc (AZN) announced that it has signed an agreement with Recordati S.p.A, granting commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination to the latter in European markets.

                  Madhu Goel headshot

                  Zoetis (ZTS) Tops Earnings & Sales in Q1, Keeps 2017 View

                  Zoetis reported earnings of 53 cents per share beating the Zacks Consensus Estimate of 48 cents.

                    What's in Store for Zoetis (ZTS) Stock This Earnings Season?

                    Zoetis Inc. (ZTS) is scheduled to report first-quarter 2017 results on May 4.

                      Why Is Zoetis (ZTS) Up 3.1% Since the Last Earnings Report?

                      Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                        Mark Vickery headshot

                        Top Research Reports for March 9, 2017

                        Today's Research Daily features new research reports on 16 major stocks, including IBM (IBM), Celgene (CELG), and Shell (RDS.A).

                          Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook

                          Zoetis Inc. (ZTS) topped earnings estimates in the fourth-quarter of 2016 while revenues came in line. The company also narrowed its outlook for 2017 to account for currency impact.

                            Ekta Bagri headshot

                            Zoetis (ZTS) Tops on Earnings in Q4, Updates View

                            Zoetis has surpassed earnings estimates in Q4 but revenues came in line. The company also updated its outlook for 2017.

                              David Bartosiak headshot

                              5 Easy Money Momentum Stocks To Buy Now

                              These 5 stocks are breaking through to new 52-week highs on huge momentum

                                Mark Vickery headshot

                                Top Research Reports for December 29, 2016

                                Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Danaher (DHR) and Colgate-Palmolive (CL).

                                  Sheraz Mian headshot

                                  Top Research Reports for Broadcom, PNC Financial & ConocoPhillips

                                  Today's Research Daily features new research reports on 16 major stocks, including Broadcom (AVGO), PNC Financial Services (PNC) and ConocoPhillips (COP).

                                    5 Healthcare Stocks Poised to Trump Q3 Earnings

                                    Medical is one of the many sectors that is witnessing earnings and revenue growth this quarter.

                                      Sheraz Mian headshot

                                      Top Research Reports for August 19, 2016

                                      Today's must-read reports are for Verizon (VZ), Comcast (CMCSA) and Teva (TEVA).

                                        Brian Hamilton headshot

                                        Bear of the Day: Valeant Pharma (VRX)

                                        The company is facing legal, accounting, and negative pricing issues.